SOLENO THERAPEUTICS INC

SOLENO THERAPEUTICS INC

Soleno Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in the United States, focused on developing therapies for rare diseases with high unmet need. The firm, publicly traded under the ticker SLNO, emerged from a merger between Soleno Therapeutics and Essentialis Therapeutics in 2017 (per SEC filings). The company's primary focus is on DCCR (diazoxide choline), a once-daily oral tablet for Prader-Willi syndrome (PWS). The company strategy centers on advancing DCCR through late-stage clinical trials, with a completed Phase 3 trial and preparations for a New Drug Application (NDA) submission to the FDA. Soleno's asset class mix is singularly focused on biotech R&D, with no diversification into other strategies. Geographically, operations are limited to the United States, though the target patient population is global. The firm has not publicly disclosed named portfolio companies or co-investors beyond its own pipeline. Total full-time employees are not disclosed, but Soleno operates with a lean, specialized team typical of clinical-stage biotechs — under 50 professionals. No additional offices beyond its headquarters in California have been publicly listed. The company has not disclosed any adjacent philanthropic or investment vehicles, functioning solely as a drug developer. Soleno's structural differentiator lies in its public-company status, which allows it to access capital markets rather than rely on a single family office or venture backing. This governance model ties decision-making to a board of directors and shareholder votes, distinct from the concentrated control of a family enterprise. The firm's reliance on FDA approval milestones creates a binary risk profile uncommon in traditional family-office portfolios.